Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

BACKGROUND: Patients with treatment-naive advanced urothelial cancer (UC) Ineligible for cisplatin-based chemotherapy are typically older and have comorbidities, representing a difficult-to-treat population. OBJECTIVE: To evaluate the safety and antitumor activity of first-line pembrolizumab in subg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eur Urol Oncol
Hauptverfasser: Grivas, Petros, Plimack, Elizabeth R., Balar, Arjun V., Castellano, Daniel, O’Donnell, Peter H., Bellmunt, Joaquim, Powles, Thomas, Hahn, Noah M., de Wit, Ronald, Bajorin, Dean F., Ellison, Misoo C., Frenkl, Tara L., Godwin, James L., Vuky, Jacqueline
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246631/
https://ncbi.nlm.nih.gov/pubmed/32423837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euo.2020.02.009
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge